Iobenguane I 131
Azedra is a radiopharmaceutical agent indicated for the treatment of iobenguane-positive unresectable, locally advanced, or metastatic pheochromocytoma and paraganglioma in adults and children 12 years and older. It delivers targeted radiation directly to neuroendocrine tumor cells that express norepinephrine transporters, providing a therapeutic option when surgery or other treatments are not feasible.
Azedra is a targeted radiopharmaceutical treatment for certain rare neuroendocrine tumors (pheochromocytoma and paraganglioma) that delivers radioactive iodine-131 directly to cancer cells.
Key facts at a glance
- RxNorm
- 2053287
- Generic
- Azedra
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Azedra is approved for the treatment of iobenguane-positive unresectable, locally advanced, or metastatic pheochromocytoma and paraganglioma in adults and children 12 years and older. It is specifically indicated for patients who require a therapeutic approach beyond standard treatments.
Azedra consists of iobenguane (MIBG) radiolabeled with iodine-131. The iobenguane component is taken up by tumor cells through norepinephrine transporters. Once inside the cell, the radioactive iodine-131 emits beta radiation that damages and destroys the tumor cells, including neighboring cells through a cross-fire effect.
Azedra requires specialized handling and administration by healthcare professionals trained in radiopharmaceutical use. It carries risks of bone marrow suppression, including thrombocytopenia and neutropenia. Patients must follow radiation safety precautions. Prior to treatment, patients must demonstrate iobenguane uptake on diagnostic imaging. Treatment involves multiple dosing with appropriate monitoring between doses.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed September 3, 2026. · Read our editorial policy